Synapse - Hematologic Malignancies, Division of

Results (226)

Understanding genomic and social determinants of cancer immunotherapy outcome across ancestry

Meeting Abstract

Fong, C. J.; Waters, M.; Pichotta, K.; Jee, J.; Jutagir, D. R.; Ma, D.; Perea-Chamblee, T.; Kim, S.; Arora, K.; Mastrogiacomo, B.; more...
Cancer Research (2023)

Fulltext@MSK | Save

Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens

Meeting Abstract

Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Jacobi, R.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
Cancer Research (2023)

Fulltext@MSK | Save

Efficacy and safety of parsaclisib-ruxolitinib combination therapy in myelofibrosis patients (Pts) with low vs higher baseline platelet count (PC): A subgroup analysis of data from a phase 2 study

Meeting Abstract

Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM

Meeting Abstract

Lonial, S.; Richard, S.; Matous, J. V.; Yee, A. J.; Shah, U.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Ailawadhi, S.; Richardson, P. G.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial

Meeting Abstract

Jäger, U.; Han, X.; Germano, D.; Quinn, D.; Gaddis, D.; Masood, A.; Mulvey, T.; Mataraza, J.; Bishop, M. R.; Salles, G.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Biomarker assessment of PTEN protein expression and gene expression profiling (GEP) in a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL)

Meeting Abstract

Chaturvedi, S.; Schulz, A.; Soler, L. M.; Childs, B. H.; Matasar, M.; Zinzani, P. L.
Cancer Research (2022)

Fulltext@MSK | Save

Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling

Meeting Abstract

Zaidi, S.; Zhao, J.; Chan, J.; Martine, R.; Wadosky, K.; Gopalan, A.; Karthaus, W.; Watson, P.; True, L.; Nelson, P.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms

Meeting Abstract

Diamond, B.; Ziccheddu, B.; Boyle, E. M.; Maclachlan, K.; Taylor, J.; Watts, J. M.; Lu, S. X.; Coffey, D. G.; Bolli, N.; Papaemmanuil, E.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Subtype-specific and structure variation induced 3D genome alteration in acute myeloid leukemia

Meeting Abstract

Xu, J.; Song, F.; Zhang, B.; Lyu, H.; Kobayashi, M.; Zhao, Z.; Hou, Y.; Wang, X.; Luan, Y.; Jia, B.; more...
Cancer Research (2022)

Fulltext@MSK | Save

RBM10 loss in thyroid cancer leads to aberrant splicing of cytoskeletal and extracellular matrix mRNAs and increased metastatic fitness

Meeting Abstract

Krishnamoorthy, G. P.; Glover, A.; Untch, B.; Saqcena, M.; Vukel, D.; Berman, K.; Abdel-Wahab, O.; Bradley, R. K.; Knauf, J. A.; Fagin, J. A.
Cancer Research (2022)

Fulltext@MSK | Save